Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

CT-388.

Research draft

CT-388 is an experimental peptide dual GLP-1 and GIP receptor agonist.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

CT-388 is an experimental peptide dual GLP-1 and GIP receptor agonist.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It uses signalling-biased receptor activation intended to influence appetite and glucose control.

Human research

Published phase 1 research provides early weight and glycaemic findings; later readouts need separate review.

Preclinical & other research

Cell and animal models characterised receptor signalling and weight-related effects.

Safety & unknowns

Early trials cannot establish rare adverse effects or long-term outcomes.

Regulatory status

Investigational in reviewed sources; not interchangeable with tirzepatide.

Reported use & evidence

Research profile draft

The supplied CT-388 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds